Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company focused on adaptive immune system genetics, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL. The company's management will engage in a fireside chat on June 11th at 5:40 a.m. PT / 8:40 a.m. ET. Investors and interested parties can access both live and archived webcasts of the presentation through the company's website investor section at www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT), un'azienda biotecnologica in fase commerciale specializzata nella genetica del sistema immunitario adattivo, ha annunciato la sua partecipazione alla 46ª Conferenza Globale Annuale sulla Sanità di Goldman Sachs a Miami, FL. Il management della società parteciperà a una chiacchierata informale il 11 giugno alle 5:40 a.m. PT / 8:40 a.m. ET. Investitori e interessati potranno seguire la presentazione in diretta o in differita tramite webcast nella sezione investitori del sito web aziendale www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT), una empresa biotecnológica en etapa comercial enfocada en la genética del sistema inmunitario adaptativo, anunció su participación en la 46ª Conferencia Global Anual de Salud de Goldman Sachs en Miami, FL. La dirección de la compañía participará en una charla informal el 11 de junio a las 5:40 a.m. PT / 8:40 a.m. ET. Los inversores y las partes interesadas podrán acceder a las transmisiones en vivo y archivadas de la presentación a través de la sección de inversores en el sitio web de la empresa www.adaptivebiotech.com.
Adaptive Biotechnologies (나스닥: ADPT)는 적응 면역 체계 유전학에 중점을 둔 상업 단계의 생명공학 회사로, 플로리다 마이애미에서 열리는 골드만삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 6월 11일 오전 5:40 PT / 오전 8:40 ET에 파이어사이드 채팅에 참여할 예정입니다. 투자자 및 관심 있는 분들은 회사 웹사이트 투자자 섹션(www.adaptivebiotech.com)을 통해 생중계 및 녹화된 웹캐스트를 시청할 수 있습니다.
Adaptive Biotechnologies (Nasdaq : ADPT), une entreprise biotechnologique en phase commerciale spécialisée dans la génétique du système immunitaire adaptatif, a annoncé sa participation à la 46e conférence mondiale annuelle sur la santé de Goldman Sachs à Miami, FL. La direction de la société participera à une discussion informelle le 11 juin à 5h40 PT / 8h40 ET. Les investisseurs et les parties intéressées pourront accéder aux webcasts en direct et archivés de la présentation via la section investisseurs du site web de l’entreprise www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT), ein Biotechnologieunternehmen in der kommerziellen Phase mit Fokus auf die Genetik des adaptiven Immunsystems, gab seine Teilnahme an der 46. jährlichen Global Healthcare Konferenz von Goldman Sachs in Miami, FL, bekannt. Das Management des Unternehmens wird am 11. Juni um 5:40 Uhr PT / 8:40 Uhr ET an einem Fireside Chat teilnehmen. Investoren und Interessierte können sowohl Live- als auch aufgezeichnete Webcasts der Präsentation über den Investor-Bereich der Unternehmenswebsite www.adaptivebiotech.com abrufen.
- None.
- None.
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL.
Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Wednesday, June 11th at 5:40 a.m. Pacific Time / 8:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
When is Adaptive Biotechnologies (ADPT) presenting at the Goldman Sachs Healthcare Conference 2025?
How can I watch Adaptive Biotechnologies' (ADPT) presentation at the Goldman Sachs conference?
What type of company is Adaptive Biotechnologies (ADPT)?
Where is the Goldman Sachs Healthcare Conference 2025 being held?
